Magorium Pte. Ltd. reposted this
Sanofi’s new S$800m manufacturing facility in Singapore will produce a wide variety of medicines and can complete a product changeover in a matter of days, rather than months. Aptly named Modulus, the plant is Asia’s first modular concept manufacturing facility and can produce up to four different biopharmaceuticals and vaccines simultaneously, allowing critical life-saving therapies and vaccines to be manufactured and scaled rapidly for patients globally. The highly digitalised, low-carbon facility features 34 standardised production modules with interconnected equipment, allowing for greater manufacturing flexibility to support pandemic preparedness. Besides adopting sustainable manufacturing practices and green technology like solar panels, recycled materials were also used in the construction of the facility – the site’s roads are built with recycled plastic from insulin pens in collaboration with local startup Magorium Pte. Ltd.. This next-generation plant will create approximately 200 specialised roles across bioprocessing, #automation, #AI, and bioinformatics. The Singapore site is part of our growing #biopharmaceutical sector, which produced over S$19b worth of high-value medicines and healthcare solutions for global markets in 2022. Read about how Modulus is advancing biopharmaceutical manufacturing capabilities globally from Singapore: https://lnkd.in/gcH-TeCV
That’s wonderful to hear! 🎉 Being part of the opening event for this new site highlights the exciting potential it holds. With the innovative work and impactful contributions expected from this site, it’s set to be a significant milestone for the industry and a great step forward for the ecosystem. 🌟🚀
What an incredible milestone for Sanofi and the global biopharmaceutical industry! The launch of Modulus in Singapore represents a groundbreaking step forward in agile, sustainable, and innovative healthcare manufacturing. By combining modular design, digital transformation, and green technology, this next-generation facility not only supports pandemic preparedness but also redefines how we think about scalable, sustainable medicine production. Initiatives like recycled plastic roads and low-carbon practices set an inspiring benchmark for sustainability in the industry. It’s exciting to see Singapore Economic Development Board (EDB) and Singapore as a society playing such a pivotal role in shaping the future of healthcare, and I look forward to witnessing the life-saving impact this facility will have on patients around the world. Congratulations to everyone involved in bringing this vision to life! 🚀🌱 #Innovation #Sustainability #Biopharma #FutureOfMedicine
Well done. After Neuville, Singapore is officially inaugurate. A 2nd awesome place to produce new Sanofi's molecules into an awesome innovative plant. Congratulations
Wow, congratulations to Sanofi and Singapore EDB! What an incredible achievement using latest modular designs, agile manufacturing, digital platforms, and sustainability.
Congratulations on achieving such a significant milestone to Sanofi and Singapore EDB, and the record speed this has been put together!
Great news 👍
Chu Xian Oh great milestone 👏
Congratulations Liang Hong Koh Vincent Ho Edwin Pao!
Executive Vice President, Head of Manufacturing and Supply
3wProud of our Manufacturing & Supply teams who entirely designed the Modulus facility in Singapore. More than just a factory, it redefines healthcare delivery with flexibility and speed, enabling us to meet the changing needs of the pipeline across multiple modalities, as well as respond with urgency to future public health challenges